Chronic lymphocytic leukemia research hub
44 indexed studies · 23 currently recruiting
- ongoing, recruitingHuman Pharmacology (Phase I)- Other
Intermittent ibrutinib in chronic lymphocytic leukemia
This study is looking at a new way to give a medicine called ibrutinib for chronic lymphocytic leukaemia (CLL). Instead of taking the medicine all the time, patients will take it in cycles, with breaks in between. This is an early study to see how safe and effective this new approach is.
Sweden · Norway - active not recruitingPHASE3
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
This study tested new treatments for Chronic Lymphocytic Leukemia (CLL), a type of blood cancer, in people who had not been treated before. It compared different drug combinations to see which worked best to slow down or stop the cancer's progress.
United States · Australia · Belgium - active not recruitingPHASE3
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
This study compares a new drug, zanubrutinib, with standard treatments (bendamustine and rituximab) for adults with previously untreated Chronic Lymphocytic Leukaemia (CLL) or Small Lymphocytic Lymphoma (SLL). Researchers want to see which treatment works best to stop the cancer from getting worse.
United States · Australia · Austria - active not recruitingPHASE3
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
This study looks at a new drug, Pirtobrutinib, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It compares Pirtobrutinib to standard treatments to see if it works better for those who have already tried other therapies.
United States · Australia · Austria - active not recruitingPHASE3
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
This study is for people who have already been taking a medicine called venetoclax for their cancer in another trial. It allows them to keep taking venetoclax if it's helping them and they're not having bad side effects, so doctors can learn more about its long-term safety.
United States · Australia · Austria - recruitingPHASE3
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
This study looks at new ways to treat Chronic Lymphocytic Leukemia (CLL), a type of blood cancer. Researchers are testing the safety of two drug combinations: venetoclax with obinutuzumab, or venetoclax with acalabrutinib. They want to see how well these treatments work and if they cause any side effects.
United States · Australia · France - recruitingPHASE2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This study is testing a new medicine called Pirtobrutinib for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It's for people who have already had some treatment for their condition, or for those who haven't had treatment but have a specific gene change.
United States · Australia · Belgium - enrolling by invitation
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
This study looks at the long-term effects of AvenCell's CAR-T cell treatments for blood cancers like lymphoma and leukemia, and also prostate cancer. It checks how safe and effective these treatments are over time for people who've already had them in past AvenCell trials.
Germany - recruitingPHASE1, PHASE2
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
This study looks at new ways to give a medicine called sonrotoclax for blood cancers like Chronic Lymphocytic Leukemia (CLL). We want to find the safest and most effective starting dose schedule, often with another medicine called zanubrutinib, to help patients.
United States · Australia · France - recruitingPHASE1
Study of SGR-1505 in Mature B-Cell Neoplasms
This study is testing a new medicine called SGR-1505 for certain types of B-cell lymphoma. We want to find out if it's safe, what dose works best, and if it can help slow down the disease. It's for people whose treatment hasn't worked or stopped working.
United States · France · Italy - recruitingPHASE4
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
This study is for people in the UK who are already taking part in a trial for a cancer medicine called pirtobrutinib. It's looking at how safe and effective the medicine is in the long term for chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
United States · Australia · France - active not recruitingPHASE3
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
This study compares a new treatment, Pirtobrutinib, with standard drugs (Venetoclax and Rituximab) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who’ve had treatment before. Researchers want to see if the new combination works better and is safe.
United States · Australia · Belgium - active not recruitingPHASE1, PHASE2
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
This study is testing a new cell therapy called rapcabtagene autoleucel for different types of blood cancers, including certain lymphomas and leukaemias. It aims to see if the treatment is safe, works well, and how best to give it, sometimes with another drug called ibrutinib.
United States · Australia · Austria - active not recruitingPHASE3
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
This study compares a new medicine, pirtobrutinib, with standard treatment (bendamustine and rituximab) for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see which is safer and works better.
United States · Australia · Austria - recruiting
Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:
This study looks at how health costs and quality of life differ between starting treatment for certain blood cancers (CLL/SLL) right away or waiting. It helps us understand the best approach for patients.
Canada - recruitingPHASE3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
This study compares a new medicine called nemtabrutinib with existing treatments (ibrutinib or acalabrutinib) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. The aim is to see if the new drug is as good or better.
United States · Australia · Belgium - recruitingPHASE3
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
This study compares a new medicine, pirtobrutinib, with ibrutinib for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It's for adults, some of whom may have had previous treatment, and some who are newly diagnosed, especially if they have a specific gene change.
United States · Argentina · Australia - not yet recruitingPHASE2
Time Restricted Eating in Haematological Malignancies
This study is looking into whether a special eating plan called Time-Restricted Eating (TRE) can help people with Chronic Lymphocytic Leukaemia (CLL). Participants will fast for 16 hours and eat for 8 hours each day to see if it affects their cancer and general health.
Canada - recruitingPHASE3
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
This study looks at a new drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It compares BGB-16673 to existing treatments in patients whose cancer has come back after trying two other types of drugs.
United States · Argentina · Australia - recruitingPHASE3
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
This study compares two treatments for high-risk chronic lymphocytic leukaemia (CLL). One involves three drugs, and the other uses two. It aims to see if the three-drug combination can better prevent the disease from getting worse.
Germany - recruitingPHASE1
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
This study is testing a new drug, ABBV-319, for people with certain types of blood cancer like lymphoma or leukemia that have come back or are not responding to current treatments. Researchers want to see if it's safe, how it moves through the body, and if it helps fight the cancer.
United States · Australia · Canada - recruitingPHASE3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
This study looks at new drug combinations for adults in the UK with a type of blood cancer called chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). It compares new treatments with current ones to see which works best and is safest for patients whose cancer has come back or not responded to previous treatments.
United States · Argentina · Australia - recruitingPHASE3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
This study offers ongoing access to a drug called ibrutinib for people already using it for certain blood cancers and conditions, who are still benefiting. It also helps gather more long-term information on how safe and effective ibrutinib is.
United States · Argentina · Australia - active not recruiting
Economic Analysis of Alliance A041202 CLL Study
This study looked at the costs and benefits of two treatments for chronic lymphocytic leukaemia (CLL) in Canada: ibrutinib with rituximab, and another therapy called BR. It checked which treatment offered better value for money and quality of life.
Canada - active not recruitingPHASE3
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
This study compares two medicines, Acalabrutinib and Ibrutinib, for people in the UK with a type of blood cancer called Chronic Lymphocytic Leukemia (CLL) that has been treated before. It wants to see which medicine works better at stopping the cancer from getting worse.
United States · Australia · Belgium - ongoing, recruitingTherapeutic exploratory (Phase II)
HOVON 139 CLL: A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of Gazyvaro (obinutuzumab) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens. (GIVE trial).
This study looks at new ways to treat chronic lymphocytic leukaemia (CLL). It combines a medicine called obinutuzumab with venetoclax to see if it helps patients who can't have standard chemotherapy. Researchers want to find out how well it works and if it can clear all signs of the cancer.
Netherlands - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia
This study is looking at a new medicine called Calquence for people with chronic lymphocytic leukemia. Researchers want to see how safe the medicine is by tracking any side effects. They will also check if it helps people get better.
Norway · Sweden · Denmark - active not recruitingPHASE1
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
This study is looking into a new tablet medicine, ABBV-525, for adults with certain B-cell cancers like lymphoma and leukaemia. It aims to check its safety, how well the body handles it, and if it could help treat these conditions.
United States · Australia · Belgium - active not recruitingPHASE1
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
This study looks at a new combination of two medicines, Ceralasertib and Acalabrutinib, for people in the UK with a specific type of blood cancer called Chronic Lymphocytic Leukaemia (CLL). It wants to find out if this combination is safe and how well it works when other treatments haven't helped.
Poland · United Kingdom - recruitingPHASE1, PHASE2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
This study is testing a new medicine called BGB-16673 for people with certain types of B-cell cancers, like lymphoma or chronic leukaemia. It aims to find the right dose and see how well it works and if it's safe. It's an early-stage trial.
United States · Australia · Brazil - recruitingPHASE4
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
This study looks at the long-term safety of a medicine called pirtobrutinib for chronic lymphocytic leukemia and non-Hodgkin lymphoma. It's for people who have already been in other pirtobrutinib studies and want to continue their treatment or follow-up.
United States · Australia · France - recruitingPHASE1, PHASE2
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
This study is testing two medicines, KRT-232 and acalabrutinib, together for people with certain types of lymphoma or leukaemia that have come back or not responded to previous treatments. Researchers want to see if this combination is safe and works well.
United States · Australia · Belgium - recruitingPHASE3
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This study compares two medicines, BGB-16673 and pirtobrutinib, for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when previous treatments haven't worked well enough. It aims to see which medicine is safer and more effective.
United States · Argentina · Australia - recruitingPHASE3
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
This study is looking at two new drug combinations for adults newly diagnosed with Chronic Lymphocytic Leukemia (CLL). It compares sonrotoclax plus zanubrutinib with venetoclax plus acalabrutinib to see which is more effective and safer for treating this type of blood cancer.
United States · Australia · Brazil - recruitingPHASE4
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This study looks at the long-term safety of a medicine called pirtobrutinib for people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). It's for those already taking part in a previous pirtobrutinib study, to continue treatment and monitoring.
United States · Australia · Austria - active not recruitingPHASE2
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
This study looks at a new drug, Iopofosine I-131, for people with certain B-cell cancers like Waldenstrom, myeloma, or lymphoma, who haven't responded well to other treatments. It aims to see how safe and effective this new approach is.
United States · Australia · Brazil - active not recruitingPHASE2
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
This study is looking at a new medicine called acalabrutinib for people with chronic lymphocytic leukaemia (CLL). It's for patients whose CLL has come back or not responded to previous treatments, and who couldn't tolerate treatment with another medicine called ibrutinib.
United States · Belgium · France - active not recruitingPHASE3
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
This study looks at new drug combinations for people with newly diagnosed chronic lymphocytic leukemia (CLL). It compares these new treatments, acalabrutinib and venetoclax (with or without obinutuzumab), to standard chemotherapy to see which works best and is safest.
United States · Argentina · Australia - recruitingNA
Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia
This study looks at how exercise and diet might help adults with chronic lymphocytic leukaemia (CLL). We're exploring if these changes can improve your fitness, immune system, and overall health over 12 weeks, with follow-up after.
United Kingdom - not yet recruiting
variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway
This study looks at how UK doctors refer people with Chronic Lymphocytic Leukaemia (CLL) to specialists. We want to understand differences in care and find ways to improve how and when patients get referred, especially in the West Midlands.
United Kingdom - active not recruitingPHASE3
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
This study is looking at a new medicine called acalabrutinib for chronic lymphocytic leukaemia (CLL). It compares acalabrutinib to usual treatments to see which works best for people whose CLL has come back or hasn't responded to previous treatment.
United States · Australia · Austria - active not recruitingPHASE2
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
This study looks at new treatments, zilovertamab vedotin alone or with nemtabrutinib, for certain B-cell lymphomas like Mantle Cell Lymphoma, Follicular Lymphoma, and Chronic Lymphocytic Leukemia. It checks how safe and effective these treatments are for people whose cancer has returned or didn’t respond to previous therapies.
United States · Brazil · Canada - active not recruitingPHASE1, PHASE2
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
This study is testing a new medicine called acalabrutinib for people with certain types of blood cancer, like chronic lymphocytic leukaemia. It's looking to see if the medicine is safe and helps treat these conditions, especially when other treatments haven't worked.
United States · Italy · United Kingdom - ongoing, recruitingTherapeutic exploratory (Phase II)
HOVON 141 CLL: A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations.
This study is looking at a new combination treatment for chronic lymphocytic leukemia (CLL) that has come back or not responded to previous treatments. It aims to see how well these medicines keep the cancer from growing and how safe they are.
Sweden · Netherlands · Belgium